Bio-Path Holdings, Inc. (NASDAQ:BPTH) Short Interest Update

Bio-Path Holdings, Inc. (NASDAQ:BPTH) was the target of a significant decline in short interest during the month of July. As of July 15th, there was short interest totalling 111,300 shares, a decline of 23.5% from the June 30th total of 145,400 shares. Approximately 5.4% of the company’s stock are short sold. Based on an average daily volume of 1,150,000 shares, the days-to-cover ratio is presently 0.1 days.

Analyst Ratings Changes

BPTH has been the topic of several analyst reports. Roth Mkm restated a “buy” rating and set a $20.00 price target on shares of Bio-Path in a report on Monday, July 8th. StockNews.com started coverage on shares of Bio-Path in a report on Thursday, May 2nd. They set a “sell” rating on the stock.

Bio-Path Stock Performance

BPTH stock remained flat at $1.77 during mid-day trading on Friday. 13,175 shares of the company’s stock traded hands, compared to its average volume of 101,416. Bio-Path has a twelve month low of $1.59 and a twelve month high of $23.00. The firm’s 50 day moving average is $2.07 and its two-hundred day moving average is $4.44.

Bio-Path (NASDAQ:BPTH) last posted its quarterly earnings results on Wednesday, May 15th. The company reported ($4.88) earnings per share (EPS) for the quarter, missing the consensus estimate of ($4.54) by ($0.34). Analysts forecast that Bio-Path will post -5.53 earnings per share for the current year.

Bio-Path Company Profile

Bio-Path Holdings, Inc operates as a clinical and preclinical stage oncology focused RNAi nanoparticle drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology platform that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction.